Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?

Diabetes & Metabolism
M CroyalM Krempf

Abstract

The benefit of the lipid-lowering drug fenofibrate on cardiovascular outcomes is controversial. Our aim was to find new circulating markers to identify those patients most likely to benefit from fenofibrate prescription. Analyses were conducted of plasma samples collected from 102 patients with type 2 diabetes, enrolled in the FIELD trial, before and after fenofibrate treatment (200mg/day). Non-targeted and targeted lipid analyses and apolipoprotein measurements were made using mass spectrometry methods. Lipidomics revealed a global decrease in ceramide after fenofibrate treatment confirmed by quantitative analysis (-18.2%, P<0.001). These changes were strongly associated with those found for plasma sphingomyelin (r=0.80, P<0.001) and, to a lesser extent, for sphingosine-1-phosphate (r=0.34, P<0.001). Ceramide levels decreased in 73.5% of patients. In addition to the expected lipid changes (decreases in triglycerides, total cholesterol and LDL cholesterol, and increase in HDL cholesterol), fenofibrate also lowered plasma apoC-II (-11.1%, P<0.01), apoC-III (-24.6%; P<0.001), apoB100 (-27.0%, P<0.01) and sphingomyelinase (-7.6%, P<0.001), and increased plasma apoA-II (22.4%, P<0.001) as well as adiponectin (11.4%, P<0.001). No si...Continue Reading

Citations

Dec 21, 2018·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Luis Felipe León-AguilarFrancisco Bolaños-Jiménez
Jul 5, 2018·Cell Death & Disease·Sophie GoulitquerLaurent Corcos
Dec 4, 2020·Journal of Diabetes and Its Complications·Nawajes MandalSam Dagogo-Jack
Dec 29, 2020·Journal of Lipid Research·Julia V Busik
Nov 3, 2020·Frontiers in Endocrinology·Mika HilvoReijo Laaksonen
Nov 19, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ivan LiakhAdriana Mika
Feb 14, 2021·Journal of Lipid Research·Julia V Busik
Jul 15, 2021·Oxidative Medicine and Cellular Longevity·Manon DurandDavid Jacobi
Oct 8, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Dolores Camacho-MuñozAnna Nicolaou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.